Rosiglitazone promotes atherosclerotic plaque stability in fat-fed ApoE

详细信息    查看全文

• 作者：Mingxue Zhou ; Hao Xu ; Lin Pan ; Jianyan Wen ; Wenqiang Liao ; Keji Chen
• 关键词：Rosiglitazone ; Plaque stability ; Atherosclerosis ; Inflammation
• 刊名：European Journal of Pharmacology
• 出版年：2008
• 出版时间：20 August 2008
• 年：2008
• 卷：590
• 期：1-3
• 页码：297-302
• 全文大小：947 K

文摘

Type 2 diabetes is considered a “risk equivalent” for cardiovascular disease, rosiglitazone, as an insulin sensitizer, has been explored as a novel therapeutic drug for the prevention of cardiovascular disease, but whether it can stabilize vulnerable atherosclerotic plaques is still unknown. Our study aims to investigate the effect of rosiglitazone on plaque stability in fat-fed ApoE-knockout mice. Our findings showed that rosiglitazone can stabilize the vulnerable atherosclerotic plaques in fat-fed ApoE-knockout mice by modifying the plaque composition as well as decreasing the number of buried fibrous caps and its anti-inflammatory effect probably is the key mechanism through which promotes the plaque more stable.